U.S. Markets open in 1 hr 7 mins

22nd Century Group, Inc. (XXII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1200+0.1300 (+4.35%)
At close: 4:00PM EDT
3.0800 -0.04 (-1.28%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9900
Open3.0200
Bid3.2300 x 2200
Ask3.2300 x 3200
Day's Range2.9600 - 3.1300
52 Week Range0.5620 - 6.0700
Volume1,008,836
Avg. Volume2,179,249
Market Cap507.209M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.1480
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
  • Investopedia

    Top Pharmaceutical Stocks for Q4 2021

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.

  • GlobeNewswire

    22nd Century Group Enters Global Specialty Hops Market

    Geographic Expansion into Europe via the NetherlandsBUFFALO, N.Y., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced entry into the global specialty hops market, its third and newest plant franchise. The Company released an update letter to shareholders from CEO James A. Mish describing its opportunities and plans in this market.

  • GlobeNewswire

    22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors

    Anthony Johnson Anthony Johnson - Board of Directors Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company’s Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced the appointment of Anthony Johnson